1. Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

2. Baseline characteristics of study population of new users and non-users of statins Values are numbers (percentages) unless stated otherwise
Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

3. Crude incidence per 10 000 person years for study outcomes in both men and women
Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

4. Risk associated with statin type both in men and in women for non-significant and marginal outcomes
Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

5. Risk of significant outcomes associated with type and dose of statin both in men and in women - Part I
Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

6. Risk of significant outcomes associated with type and dose of statin both in men and in women - Part II
Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

7. Relative incidence rate ratios from case series analysis for men and women combined for significant outcomes associated with statin type
Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

8. Numbers needed to harm (NNH) or numbers needed to treat (NNT) and numbers of extra or prevented cases for each outcome over five years in patients aged free of cardiovascular disease at baseline with QRISK2 score of ≥20% or ≥15%
Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197